A multimodal evaluation of transcranial photobiomodulation in mild cognitive impairment: Cognitive, metabolic, and neuroimaging outcomes of a pilot randomized controlled trial
Rashidi-Ranjbar N, Churchill NW, Jerkic M, Zomorrodi R, Rotstein O, Schneider R, Andreazza AC, Rajji TK, Graham SJ, Munoz DG, Fornazzari L, Lim L, Norris M, Schweizer TA, Fischer CE
Journal of Alzheimer's disease : JAD · 0 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Posiblemente financiado por la industria
- Empresa
- Hilary and Galen Weston Foundation
- Empresa
- Temerty-Tanz-TDRA
- Sin clasificar
- TDRA-MITO2i
Según 3 financiadores declarados.
Publicación
- Publicado
- 2026-06-03 · J Alzheimers Dis · vol. 112 · número 3 · págs. 1445–1458
- Editorial
- IOS Press
- Citado
- 0 citas · más que el 43% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 56 trabajos
- Acceso
- De pago
- Áreas de investigación
- Laser Applications in Dentistry and Medicine · Transcranial Magnetic Stimulation Studies · Optical Imaging and Spectroscopy Techniques
- Palabras clave
- transcranial photobiomodulation, mild cognitive impairment
- MeSH
- brain, humans, magnetic resonance imaging, treatment outcome, pilot projects, single-blind method, cognition, neuropsychological tests, aged, middle aged, female, male, neuroimaging, low-level light therapy, cognitive dysfunction, cognitive enhancement
15 autores
- Neda Rashidi‐Ranjbar🇨🇦St. Michael's Hospital
- Nathan W. Churchill🇨🇦St. Michael's Hospital
- Mirjana Jerkić🇨🇦St. Michael's Hospital
- Reza Zomorrodi🇨🇦Centre for Addiction and Mental Health
- Ori David Rotstein🇨🇦St. Michael's Hospital; University of Toronto
- Raphaël Schneider🇨🇦St. Michael's Hospital; University of Toronto
- Ana C. Andreazza🇨🇦University of Toronto
- Tarek K. Rajji🇨🇦🇺🇸Centre for Addiction and Mental Health; The University of Texas Southwestern Medical Center
- Simon J. Graham🇨🇦Sunnybrook Health Science Centre; University of Toronto
- David G. Munoz🇨🇦St. Michael's Hospital; University of Toronto
- Luis Fornazzari🇨🇦St. Michael's Hospital
- Lew Lim
- Mireille Norris🇨🇦University of Toronto
- Tom A. Schweizer🇨🇦St. Michael's Hospital; University of Toronto
- Corinne Eleanor Fischer🇨🇦 · autor de correspondenciaSt. Michael's Hospital; University of Toronto
Resumen
El texto original del estudio, en el idioma en que se publicó.
BackgroundMild cognitive impairment (MCI), a prodromal stage of Alzheimer's disease and related dementias (ADRD), represents a critical window for intervention. Although mitochondrial dysfunction is increasingly implicated in neurodegeneration, most therapies target downstream protein aggregation. Transcranial photobiomodulation (tPBM) delivers near-infrared light to enhance mitochondrial respiration.ObjectiveWe hypothesized that tPBM in MCI would be safe, feasible, and associated with improvements in cognition, mitochondrial function, and default mode network (DMN) functional connectivity (FC).MethodsWe conducted a single-blind, randomized, sham-controlled pilot trial (NCT05563298) in adults ≥50 years with MCI. Twenty participants were randomized 1:1 to active or sham devices. Active devices delivered pulsed 810-nm light for 20 min per session; shams emitted light for 2 seconds. Stimulation targeted DMN hubs and the olfactory bulb. Participants self-administered treatment at home six days per week for six weeks.ResultsAdherence was high (active 96.9%; sham 94.2%). Adverse events (AEs) were reported by 10 of 20 participants (4 active, 6 sham). No serious AEs occurred. Compared with sham, active tPBM produced greater improvement in global cognition (Mini-Mental State Examination; p = 0.03, d = 1.05) and episodic memory (California Verbal Learning Test-II long-delay recognition; p = 0.02, d = 1.09). Serum pyruvate and lactate increased with a reduced lactate-to-pyruvate (L/P) ratio (p = 0.007, d = -1.37). DMN FC increased (p = 0.014, d = 1.25), and plasma IL-6 declined (p = 0.02, r = -0.52).ConclusionsHome-based tPBM was safe, well tolerated, and feasible, with high adherence and mild AEs. Cognitive, metabolic, and network-level findings are consistent with enhanced mitochondrial efficiency and anti-inflammatory effects. These results support larger, double-blind, multicenter trials to evaluate tPBM as a mitochondria-targeted therapy in early ADRD.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.